Literature DB >> 21694737

Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.

D Gareth R Evans1, Catherine O'Hara, Anna Wilding, Sarah L Ingham, Elizabeth Howard, John Dawson, Anthony Moran, Vilka Scott-Kitching, Felicity Holt, Susan M Huson.   

Abstract

Neurofibromatosis 1 (NF1) is a comparatively common autosomal dominant disorder. However, relatively few studies have assessed lifetime risk; and information about the effect of NF1 on mortality remains uncertain. NF1 patients were identified using The North West regional family Genetic Register, which covers the 4.1 million people living in North West England, including the regions of Greater Manchester, Cheshire and Cumbria. Data relating to tumours and malignancies were obtained from The North West Cancer Intelligence Service. Death data for the general North West population were obtained from the Office of National Statistics. We identified 1186 individuals with NF1, of whom 1023 lived within the strict regional boundaries (constituting a region of North West England bound by The Pennines to the east and Irish Sea to the west, but excluding the conurbation of Liverpool (Merseyside) and the Wirral peninsula) and 131 had died. MPNST and glioma were found to be the two most common causes of reduced life expectancy among NF1 patients. In Kaplan-Meier analyses the median survival for NF1 patients was shown to be 71.5 years, with women living ∼7.4 years longer than men. On average both men and women lived ∼8 years less than their counterparts in the general population. Reduction in life expectancy for NF1 patients was found to be much lower (8 years) than the previously estimated 15-year decrease. Limitations relating to the underreporting of NF1 on death certificates were once again highlighted and should be considered in future investigations.

Entities:  

Mesh:

Year:  2011        PMID: 21694737      PMCID: PMC3198144          DOI: 10.1038/ejhg.2011.113

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

1.  Sarcomas in three generations of a family with neurofibromatosis.

Authors:  A L Hartley; J M Birch; A M Kelsey; M Harris; P H Jones
Journal:  Cancer Genet Cytogenet       Date:  1990-04

2.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Authors:  S M Huson; D A Compston; P Clark; P S Harper
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

Review 3.  NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.

Authors:  J J Mulvihill; D M Parry; J L Sherman; A Pikus; M I Kaiser-Kupfer; R Eldridge
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

4.  Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms.

Authors:  S A Sørensen; J J Mulvihill; A Nielsen
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

5.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

6.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

Authors:  S A Rasmussen; Q Yang; J M Friedman
Journal:  Am J Hum Genet       Date:  2001-03-28       Impact factor: 11.025

7.  Neurofibromatosis in Gothenburg, Sweden. I. Background, study design and epidemiology.

Authors:  B Samuelsson; S Samuelsson
Journal:  Neurofibromatosis       Date:  1989

8.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

9.  Mortality of neurofibromatosis in Japan, 1968-1992.

Authors:  Y Imaizumi
Journal:  J Dermatol       Date:  1995-03       Impact factor: 4.005

10.  Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

Authors:  Allison King; Robert Listernick; Joel Charrow; Linda Piersall; David H Gutmann
Journal:  Am J Med Genet A       Date:  2003-10-01       Impact factor: 2.802

View more
  53 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.

Authors:  Ye Won Jeon; Ra Mi Kim; Seung Taek Lim; Hyun Joo Choi; Young Jin Suh
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

4.  Incidence and mortality of neurofibromatosis: a total population study in Finland.

Authors:  Elina Uusitalo; Jussi Leppävirta; Anna Koffert; Sakari Suominen; Jussi Vahtera; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  J Invest Dermatol       Date:  2014-10-29       Impact factor: 8.551

5.  Comment on the article "Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri" by van den Munckhof et al.

Authors:  Trine E Prescott; Miriam J Smith; D Gareth Evans
Journal:  Neurogenetics       Date:  2011-12-28       Impact factor: 2.660

6.  Increased risk of breast cancer in women with NF1.

Authors:  Sara Aileen Madanikia; Amanda Bergner; Xiaobu Ye; Jaishri O'Neill Blakeley
Journal:  Am J Med Genet A       Date:  2012-11-19       Impact factor: 2.802

7.  Delineation of the clinical phenotype associated with non-mosaic type-2 NF1 deletions: two case reports.

Authors:  Julia Vogt; Rosa Nguyen; Lan Kluwe; Martin Schuhmann; Angelika C Roehl; Tanja Mußotter; David N Cooper; Victor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  J Med Case Rep       Date:  2011-12-12

8.  Educational delay and attainment in persons with neurofibromatosis 1 in Denmark.

Authors:  Karoline Doser; Line Kenborg; Elisabeth Wreford Andersen; Pernille Envold Bidstrup; Anja Kroyer; Hanne Hove; John Østergaard; Sven Asger Sørensen; Christoffer Johansen; John Mulvihill; Jeanette Falck Winther; Susanne Oksbjerg Dalton
Journal:  Eur J Hum Genet       Date:  2019-02-28       Impact factor: 4.246

9.  Comprehensive pharmacological profiling of neurofibromatosis cell lines.

Authors:  Jianman Guo; Michael R Grovola; Hong Xie; Grace E Coggins; Patrick Duggan; Rukhsana Hasan; Jiale Huang; Danny W Lin; Claire Song; Gabriela M Witek; Simon Berritt; David C Schultz; Jeffrey Field
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

10.  Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.

Authors:  Jianman Guo; Katherine E Chaney; Kwangmin Choi; Gabriela Witek; Ami V Patel; Hong Xie; Danny Lin; Kanupriya Whig; Yao Xiong; David C Schultz; Nancy Ratner; Jeffrey Field
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.